## EMN: Eastman Chemical Company - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_10 0.3% below STRENGTH zone (3.0-6.0%); PEG 3.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($59.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 3, Bearish: 1)

**1. Eastman Chemical (EMN): Citigroup Raises Price Target to $72 | E**
- Source: GuruFocus | 20251218T200053 | Bullish | Relevance: 100%
- Citigroup analyst Patrick Cunningham has maintained a "Buy" rating for Eastman Chemical (EMN) and increased the price target from $70 to $72, reflecting a 2.86% rise and a positive outlook. This adjustment comes despite several other analysts lowering their price targets for EMN in recent months. The average one-year price target from 17 analysts is $73.20, implying a 14.02% upside from the current price.

**2. Eastman Chemical price target raised to $72 from $70 at Citi**
- Source: TipRanks | 20251218T120948 | Bullish | Relevance: 100%
- Citi has increased its price target for Eastman Chemical (EMN) to $72 from $70, maintaining a Buy rating on the shares. This adjustment comes as part of Citi's 2026 outlook for the chemicals group, indicating a more positive stance on lithium fundamentals. The firm also updated estimates and targets due to its less optimistic view on polyethylene producers.

**3. Eastman, AstraZeneca, Kraft Heinz, and P&G Recognized with OMP Supply Chain Awards**
- Source: USA Today | 20251217T162557 | Bullish | Relevance: 87%
- Eastman, AstraZeneca, Kraft Heinz, and P&G were honored at the OMP Conference for their significant contributions to supply chain planning innovation and excellence. Eastman received the Long-Term Partnership Award for co-shaping Unison Planningâ„¢, AstraZeneca earned the Innovation Award for AI-driven planning, and Kraft Heinz and P&G were recognized with the Excellence Award for their sustained commitment to advancing digital supply chain planning. The awards highlight these companies' leadership in setting new industry benchmarks and driving real-world results.

**4. Wells Fargo cuts chemicals ratings, says downturn likely to extend into 2026**
- Source: Investing.com | 20251219T190839 | Bearish | Relevance: 79%
- Wells Fargo has downgraded several major U.S. chemical companies, including Air Products, Celanese, Eastman Chemical, and LyondellBasell, citing weak demand and limited visibility that is expected to prolong the sector's downturn into at least the first half of 2026. The bank's industry checks indicate continued pressure from soft demand, customer destocking, and margin compression, with few signs of improvement for the coming year. Despite a cautious outlook for much of the sector, Wells Fargo recommends high-quality names like Linde, DuPont, and International Flavors & Fragrances, and maintains a positive stance on paint makers due to more resilient earnings.

**5. AZZ Inc. (AZZ): A Bull Case Theory**
- Source: Finviz | 20251218T103600 | Neutral | Relevance: 64%
- This article summarizes a bullish thesis on AZZ Inc. (AZZ), highlighting its strategic transformation into a focused metal coatings solutions company. AZZ benefits from high-margin core businesses, including Metal Coatings and Precoat Metals, serving infrastructure, construction, and industrial markets with durable competitive advantages. The company has also aggressively deleveraged through the monetization of its Infrastructure Solutions exposure.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Wells Fargo | $70 | $70 | 0% |
| 2025-12-18 | Citigroup | $72 | $70 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Wells Fargo | down | Equal-Weight |
| 2025-12-18 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.6% (-2.2%)
- Blackrock Inc.: 7.0% (+0.9%)
- State Street Corpora: 5.0% (+24.3%)
- Capital Research Glo: 3.7% (-1.0%)
- Dimensional Fund Adv: 3.5% (+14.4%)

### Key Risks

1. Valuation risk: PEG 3.9x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 11.7% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.87 signals overvaluation risk, limited margin of safety. Forward P/E 10.3x attractive for 14% earnings growth. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $7.3B |
| Beta | 1.25 |
| 52W Range | $56.11 - $103.82 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.87 |
| Forward P/E | 10.3 |
| Current P/E | 11.7 |
| YoY Growth | 13.5% |
| EPS Direction | FALLING |

### Technicals

MRS_10 deteriorating from 5.1% to 0.3% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.7pp (needs >3.0% for momentum thesis). MRS_5 (-1.6%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.88x), long-term trend not supportive. RSI neutral at 55. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.28% (CS: 60) | Neutral |
| RSI_14 | 54.9 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 1.020x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 0.883x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $63.55
- **Stop Loss:** $59.89 (5.8% risk)
- **Target:** $67.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 245
- **Position Value:** $15,569.75
- **Portfolio %:** 15.57%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-29 (Est: $0.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.14 | -2.2% |
| 2025Q2 | $1.75 | $1.60 | -8.7% |
| 2025Q1 | $1.89 | $1.91 | +1.2% |
| 2024Q4 | $1.57 | $1.87 | +18.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*